Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- Check3 days agoChange DetectedAdded Revision: v3.3.4; removed related topics 'Ovarian cancer' and 'MedlinePlus Genetics', and removed 'Revision: v3.3.3'.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedNew Locations section added with Ohio and Wisconsin sites, replacing the previous separate Ohio Locations and Wisconsin Locations sections.SummaryDifference0.3%

- Check53 days agoChange DetectedAdded Revision: v3.3.2 to the revisions section. Deleted Revision: v3.2.0 from the revisions history.SummaryDifference0.0%

- Check61 days agoChange DetectedRemoved an administrative notice about government funding and operating status. The content now focuses on the study details and locations.SummaryDifference0.3%

- Check82 days agoChange DetectedNew screenshot indicates minor text edits and formatting adjustments with no changes to the core study details, interventions, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check104 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference2%

Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.